<DOC>
	<DOCNO>NCT02924285</DOCNO>
	<brief_summary>For therapy symptomatic premature ventricular complex ( PVCs ) subject structural heart disease current European Guidelines management patient ventricular arrhythmias prevention second cardiac death recommend catheter ablation well amiodarone class IIa indication . Due lack randomize data study investigate comparison catheter ablation antiarrhythmic drug therapy PVC treatment patient structural heart disease . Therefore , patient randomize one two treatment strategy : 1 ) catheter ablation , 2 ) antiarrhythmic drug therapy ( amiodarone , flecainide/propafenone compatible underlying heart disease ) .</brief_summary>
	<brief_title>Catheter Ablation Versus Antiarrhythmic Drugs Therapy Premature Ventricular Contractions Patients With Structural Heart Disease</brief_title>
	<detailed_description>Premature ventricular contraction ( PVCs ) frequently encounter patient without structural heart disease . Even though PVCs healthy subject consider benign arrhythmia . There also evidence risk reversible cardiomyopathy due PVC-induced inter- intraventricular dyssynchrony . Data show elimination PVCs catheter ablation lead improvement leave ventricular dysfunction . In one-half heart failure patient frequent PVCs occur 1000/24 h. In patient structural heart disease premature ventricular contraction ( PVCs ) lead increase mortality risk burden 10 PVC per hour . Further decrease leave ventricular function worsen heart failure describe . Therefore , therapy frequent monomorphic PVCs recommend subject . Beta-blockers part standard therapy often remain ineffective may lead paradoxic effect patient bradycardia . A limiting factor selection antiarrhythmic drug due increase mortality presence structural heart disease . So case amiodarone indicate . There data show improvement LV function suppression PVCs amiodarone significant 75 % reduction baseline . However , adverse effect amiodarone well-known especially long-term therapy . On hand , radiofrequency catheter ablation widely apply safe treatment option PVCs high acute success rate 90 % PVC reduction various circumstance like pre-existing heart failure post myocardial infarction subject . Some small-sample study show benefit catheter ablation subject depress LV function . To date , randomize data comparison catheter ablation antiarrhythmic drug therapy PVCs patient structural heart disease .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ventricular Premature Complexes</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Propafenone</mesh_term>
	<criteria>Structural heart disease without leave ventricular dysfunction PVCs Holter monitoring ( burden &gt; 10.000/d ) OR PVCs Holter monitor correlate symptom OR Reduction biventricular pace &lt; 92 % subject implant cardiac resynchronization therapy ( CRT ) device Age : 1887 year Willing capable give informed consent Physical status allow electrophysiological study ( e.g . intracardiac thrombus pregnancy ) Previous PVC ablation without success New York Heart Association ( NYHA ) functional class IV Manifest hyperthyroidism Pulmonary fibrosis QTc â‰¥ 500 m ( Bazett ) screen ECG QRS &lt; 120 m ( case bundle branch accord JT interval reference ) Sick Sinus Syndrome bradycardia without implanted pacing device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>87 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>